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Translocation-in-liposarcomaRNA-seq technologies are now replacingmicroarrays for proﬁling gene expression. Herewe describe a robust RNA-
seq strategy formultiplex analysis of RNA samples based on deep sequencing. First, an oligo-dT linked to an adaptor
sequence is used to prime cDNA synthesis. Upon solid phase selection, second strand synthesis is initiated using a
randomprimer linked toanother adaptor sequence. Finally, the library is released fromthebeadsandampliﬁedusing
a bar-coded primer together with a common primer. This method, referred to asMultiplex Analysis of PolyA-linked
Sequences (MAPS), preserves strand information, permits rapid identiﬁcation of potentially new polyadenylation
sites, and proﬁles gene expression in a highly cost effective manner. We have applied this technology to determine
the transcriptome response to knockdown of the RNA binding protein TLS, and compared the result to current
microarray technology, demonstrating the ability of MAPS to robustly detect regulated gene expression.l rights reserved.© 2011 Elsevier Inc. All rights reserved.1. Introduction
RNA-seq has the obvious advantage over microarray in proﬁling
gene expression, in that it generates digital information of individual
annotated genes with literally unlimited dynamic range. In addition,
RNA-seq has the ability to comprehensively detect novel transcripts
and mRNA variants resulting from alternative promoter usages, splice
sites, and polyadenylation.
Many RNA-seq protocols have been developed in recent years (for
review, see [1,2]). Standard RNA-seqprocedure uses fragmentedRNA to
prepare dsDNA followed by adaptor ligation [3]. Thismethodminimizes
a bias towards the 3′ end of genes by converting poly(A+) RNA to cDNA.
However, this approach providesno strand information,which is crucial
for detection of anti-sense transcripts from genes within genes or
transcriptionwithin overlapping genic regions inopposite directions. To
overcome these shortcomings, various strategies have been developed
to preserve the strand information, including (1) the use of different
adaptors at the 5′ and 3′ ends [4,5], (2) 3′ end polyA tailing [6], (3)
double-random priming with distinct adaptors [7,8], and (4) dUTP
marking of the 2nd strand followed by selective degradation of the
strand after linker ligation in order to sequence only the 1st strand [9].
While these methods have the ability to detect structural variations
inmRNA, the counts generateddependonboth abundance and length of
individual transcripts. As a result, rare but long transcripts are more
easily quantiﬁed than rare but short transcripts; the latterwould require
a much higher overall tag density to detect. For the purpose of geneexpression proﬁling, the alternative approach focuses on the 3′ end of
each gene which, like the original SAGE technology, is referred to 3′-tag
digital geneexpression [10,11]. Key steps of themethod include cleavage
of dsDNA with a frequent restriction enzyme, adaptor ligation, and
afﬁnity puriﬁcation of biotinylated oligo-dT initially used to prime cDNA
synthesis. It has been demonstrated that this approach is more robust in
detecting low abundant mRNAs [10]. Another obvious advantage of this
method is its ability to systematically identify polyadenylation sites,
which has been applied to Caenorhabditis elegans [11].
Here we describe a much simpler version of the 3′-tag digital gene
expression approach, which we refer to as Multiplex Analysis of
PolyA-linked Sequences (MAPS). Thismethod, which is modiﬁed from
our original double-random priming strategy [7], uses biotinylated
oligo-dT directly linked to a speciﬁc sequencing adaptor to prime
cDNA synthesis. This is followed by second strand synthesis using a
random primer attached to a second adaptor. Using this technology,
we detected N10,000 previously unannotated polyadenylation sites in
HeLa cells and characterized the transcriptional response to knock-
down of the Pol II-associated RNA binding protein, TLS in comparison
with microarray. Our analysis has demonstrated the robustness of
MAPS in studying regulated gene expression.
2. Results and discussion
2.1. Experimental design forMultiplexAnalysis of Poly(A)-linked Sequences
(MAPS)
Our strategy, depicted in Fig. 1, employs an oligo-dT linked to a
speciﬁc sequencing primer (B) corresponding to the P7 sequence
anchored on the surface of Illumina ﬂowcells to prime cDNA
Fig. 1. Multiplex Analysis of PolyA-linked Sequences (MAPS). Total RNA is reverse
transcribed using a primer containing oligo-dTNN linked to Primer B sequencing primer
with a biotin in the 5′ end. The cDNA is captured and extended using a random primer
attached to a sequencing primer. The cDNA sequence is PCR ampliﬁed using a primer
containing sequencing primer A, a speciﬁc address (bar-code), and the sequencing
adaptor in combination with Primer B. The PCR product is gel puriﬁed and sequenced
ﬁrst with the sequencing adaptor to determine the cDNA sequence, and second with
Primer A to determine the unique bar-code.
267K. Fox-Walsh et al. / Genomics 98 (2011) 266–271synthesis. The 3′ end of the primer contains two random nucleotides
(note that the last nucleotide N corresponds to A, G or C, but not T. See
Methods) in order to ensure cDNA synthesis from the beginning of the
poly(A) tail. The primer also carries a biotin moiety for solid phase
selection. Excess oligo-dT is removed after cDNA synthesis and the 3′
end of cDNA is blocked by using terminal transferase in the presence
of ddNTP. Following biotin selection, second strand synthesis is
performed directly on magnetic beads using a random primer (8X)
linked to a speciﬁc sequencing adaptor. After washing, the second
strand is released from the beads by heat and eluted products are
ampliﬁed using Primer B in combination with a bar-coded primer. The
bar-coded primer consists of the Illumina sequencing primer (A),
which enables the ampliﬁed sequence to anneal to the P5 primer on
the Illumina ﬂowcell, followed by a 4-nucleotide coded region
(address), and the sequencing adaptor. The PCR products, while
approximately within the same size region (see below), are size
selected from acrylamide gel to minimize short fragments, quantiﬁed,
and loaded onto an Illumina ﬂowcell for deep sequencing.
Two rounds of sequencing are performed, starting with the insert,
using the sequencing adaptor for 32 to 34 cycles of sequencing. The
products are next stripped off the surface of the ﬂowcell and a secondround of sequencing is performed using primer A to identify the bar-
coded region. In our hands, both sequencing reactions can be
accomplished with the standard 36 cycle kit (because of extra
sequencing reagents included in the kit). The sequences of bar-
coded regions allow the assignment of individual samples in a
multiplex run. We have successfully decoded N99% of the sequences
using this method.
We build in two key features in the MAPS strategy. First, second
strand synthesis is initiated by simple randompriming. This method is
much simpler than dsDNA synthesis followed by restriction digestion
and linker ligation, which is currently used in the 3′-tag digital gene
expression protocol. Although in theory random priming can take
place anywhere on the ﬁrst strand cDNA, the following PCR reaction
ensures biased ampliﬁcation of short fragments from the 3′ end of
expressed genes.
The second feature of the MAPS strategy is obviously the ease of
multiplexing samples using individual bar-coded primers. Our
strategy is distinct from standard protocols using bar-coded adaptors
during library construction because it ensures all library construction
is performed under uniform conditions without the concern of
differences in quality among different bar-coded adaptors. In our
applications, we routinely multiplex 6 reactions, typically 3 biological
repeats of control and 3 treated samples in one lane of the Illumina
GAII Analyzer. Multiplexing 6 reactions in a single lane permits the
use of simple statistical analysis between differentially expressed
genes. This level of multiplexing also achieves the economy of
genome-wide analysis, as the cost for transcriptome analysis is ~$100
per sample, which is comparable to current microarray platforms. In
future applications using HiSeq2000, it should be possible to
multiplex 18 or more samples per lane, thus dramatically reducing
the cost of gene expression proﬁling to a mere $35 per sample.
2.2. Detection of known and potential new polyadenylation sites in the
human genome
We ﬁrst applied theMAPS strategy to total RNA isolated fromHeLa
cells, demonstrating the high reproducibility of this approach
(Fig. 2A). From three biological repeats, we obtained ~15 M tags,
among which ~10 M were uniquely mapped to the human genome
(the control row in Table 1). We removed potential internal priming
events [12], resulting in ~8.3 M tags, which were used for further
analysis. As expected, the tags were clustered at the 3′ end of genes,
~300 nt upstream of the polyA site (Fig. 2B). The two gene examples
provided clearly indicate that MAPS is able to detect both unique and
alternative polyadenylation sites (Fig. 2C and D).
We next clustered the tags based on annotated polyA sites,
resulting in 8859 clusters (Table 2, control). By scanning against 13
polyA signal variant motifs [13], we found that 7547 (85.2%) clusters
contain a known polyA signal within the cluster, with remaining 1312
(14.7%) clusters lacking a canonical polyA signal. This rate is similar to
that found in C. elegans[11]. Strikingly, we also detected 12,532
potential new polyA sites in the human genome, ~80% of which are
also associated with a polyA signal (Table 2). This observation
suggests that there are a huge number of polyA sites, either within
known genes or associated with new transcripts, that remain to be
annotated in the human genome. Therefore, our method can be used
not only to detect those signals, but also analyze differential
polyadenylation in future studies.
2.3. Proﬁling FUS/TLS-regulated gene expression
We next applied the MAPS strategy to proﬁle gene expression in
response to knockdown of FUS/TLS in HeLa cells. FUS/TLS is an RNA
binding protein originally identiﬁed as a frequent chromosome
translocation partner in liposarcomas [14–19]. The FUS/TLS gene
product has been implicated in multiple levels of regulated gene
Fig. 2. Identiﬁcation of the 3′ end-linked sequence tags by MAPS. (A) Reproducibility of MAPS. (B) Distribution of tags relative to known polyA sites of annotated genes. The data also
reveal the location of tags within a 300 nt window upstream of the polyA site in most cases. Examples of tags mapped to genes with a single (C) and double (D) polyA sites.
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damage-induced transcriptional response [20,21]. In addition, FUS/
TLS has been found to associate with the splicing machinery,
indicating that it may play a critical role in coupling between
transcription and RNA processing [22–26]. Most recently, FUS/TLS
was linked to Amyotrophic Lateral Sclerosis (ALS) [27,28]. We used
RNAi to achieve efﬁcient knockdown of FUS/TLS in HeLa cells (Fig. 3A).
Both control and speciﬁc RNAi-treated samples were subjected to
library preparation according to MAPS followed by deep sequencing
in a single lane on an Illumina ﬂowcell. After ﬁltering tags likely
resulting from internal priming, we obtained ~8 M uniquely mapped
tags under FUS/TLS knockdown conditions. This result is comparable
to those from control siRNA-treated cells (Table 1). Similar to control
cells, FUS/TLS knockdown samples were highly reproducible when
comparing between biological repeats (data not shown), and again,
more than half of tag clusters weremapped outside known polyA sites
(Table 2). By comparing between control and speciﬁc RNAi-treatedTable 1
Statistics of sequencing data.
Sample Total
decoded
After removal of adaptor and polyA,
Remaining tag lengthN=16
Mappable Unique
mapped
No
internal
priming
TLS KD 13537523 12892715 11984201 9323591 7939799
Control 16394011 14936999 13366509 10057514 8322360cells, we identiﬁed several hundred genes that were either up- or
down-regulated in response to in vivo depletion of FUS/TLS (Fig. 3B).2.4. Comparison with microarrays
In order to validate the data generated byMAPS on the global scale,
we performed microarray analysis on the same sets of samples from
control and FUS/TLS RNAi-treated cells (Fig. 4A). We observed a
similar pattern to previously documented comparisons of RNA-seq
and microarray platforms [29]. As noted before, microarray intensity
appears larger than RNA-seq counts, likely due to elevated back-
ground on the microarray. We next compared differentially regulated
genes, demanding FDR=b0.05 and fold change (FC)=N2 (Fig. 4B).
While the two platforms generally agree with one another in terms ofTable 2
Association of tag clusters with known and potential new polyA signals.
Clusters With polyA signal Without polyA signal
Control:
With known gene 3′end 7547 (85.2%) 1312 (14.7%)
Other 9,966 (79.5%) 2566 (20.5%)
TLS KD:
Clusters With polyA signal Without polyA signal
With known gene 3′end 5772 (85.8%) 952 (14.2%)
Other 6002 (77.6%) 1728 (22.4%)
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Fig. 3. Differential gene expression in response to FUS/TLS knockdown. (A) Top panel: Western gel comparing FUS/TLS and actin protein levels after treatment with control and FUS/
TLS siRNA; lower panel: scatter plot compares control and FUS/TLS siRNA-treated samples. (B) Detection of FUS/TLS regulated genes on the M/A plot. Differentially regulated genes
(FDRb0.05) are labeled red.
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Fig. 4. Comparison between MAPS and microarray. (A) Comparison between signal intensity detected by microarray and count by MAPS on individual annotated genes.
(B) Comparison between differentially regulated genes by FUS/TLS identiﬁed by microarray and MAPS based on FDR=b0.05 and fold change (FC)=N2. (C) Venn diagram of
differentially regulated genes uniquely or commonly detected by the two methods.
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genes, it is clear that a large number of genes that scored quantitative
differences failed to show differences on the microarray platform
(green dots). As a result, the RNA-seq data revealedmore quantitative
differences than the microarray (Fig. 4C). We also noted that,
although there were a number of genes (104) that were only
identiﬁed as differentially expressed according to the microarray
(blue dots), those genes tended to show differences slightly above the
fold cut-off (Fig. 4B). Previous analyses show similar patterns of
agreement and discrepancy between microarray and RNA-seq
platforms [29]. We have also tested the reproducibility and multiplex
capacity of MAPS technology. To do this, we compared the same
samples and multiplexed three or six samples at once in a lane
(Supplementary Fig. 1). The number of reads per gene is slightly
reduced when multiplexing at a higher level, but importantly, the
relative amount of gene is virtually identical. The ability of MAPS to
detect more differentially expressed genes than microarray suggests
that the digital method is more suitable for quantitative analysis of
regulated gene expression. Further, the ability of MAPS to effectively
multiplex with six samples in a highly reproduciblemanner illustrates
the power and monetary beneﬁt of this technology.
3. Conclusions
Wedescribe amultiplex strategy for proﬁling gene expression. The
procedure is much simpler than existing 3′-tag digital gene
expression analyses and is highly cost effective compared to
microarray-based approaches. The MAPS strategy provides strand
information, thus permitting accurate assignment of sequence tags
from the transcription of both sense and antisense strands within
many gene loci. In addition to quantitative analysis of gene
expression, our method can also be applied to detect new poly-
adenylation sites. We suggest a large number of these sites identiﬁed
have yet to be annotated. Although, some of these new polyA-
containing transcripts correspond to non-coding RNAs expressed at
low levels, their biological importance is appreciated. We have
applied this technology to study regulated gene expression by FUS/
TLS, a RNA binding protein implicated in diverse biological processes,
illustrating that this method can be applied to study a multitude of
different speciﬁc conditions. MAPS is a simple technique that enables
high quality, accurate and digital gene expression data at an
economical cost.
4. Materials and methods
4.1. Cell culture and RNA isolation
HeLa cells cultured in DMEM plus 10% FBS were transfected using
Lipofectamine 2000 (Invitrogen) with 50 pmol/ml of either TLS/FUS
siRNA 5′-ACAGCCCATGATTAATTTGTA-3′ or control siRNA for 64 h.
The cells were subsequently harvested using Trizol followed by an
Ambion RNA easy clean up. The resulting RNA was split into two
samples, one for microarray analysis and the other for RNA-seq.
4.2. Multiplex RNA-seq
Total RNA (1–3 μg) was added to 1 μl of 50 μM Bio-B-TNN (Biotin-
5′-CAAGCAGAAGACGGCATACGAGTTTTTTTTTTTTTTTTTTTTNV-3′,
note that the sequence at the 5′ portion corresponds to Primer B or P7
on the Illumina ﬂowcell and that V in the last position represents A, G,
or C, but not T), 1 μl of 10 mM dNTPs and distilled water to a total of
13 μl. The mixture was heated for 5 min at 65 °C, and subsequently
incubated on ice for at least 1 min. After the samples were cooled, 4 μl
of 5X First-strand buffer (Invitrogen), 1 μl of 0.1 M DTT, 1 μl RNase
Inhibitor (Invitrogen), and 1 μl Superscript III RT (Invitrogen) were
added to the reaction. The reaction was incubated at 50 °C for 60 min.To inactivate the reaction, 80 μl of water was added and the sample
was heated at 70 °C for 15 min. To concentrate and remove free
biotinylated oligos, the reaction along with 500 μl of Qiagen PCR
puriﬁcation buffer (Qiagen PCR Puriﬁcation Kit Cat # 28104) was
added to the column. After washing the Qiagen column once with the
binding buffer and twice with wash buffer, the cDNA was then eluted
with 50 μl of Qiagen elution buffer (Tris–HCl pH 8.5).
The eluted 50 μl sample was added to a mixture of 15 μl of 10X
terminal transferase buffer (NEB cat #M0315S), 3 μl of 130 μM ddNTP
mix, 80 μl of distilled water, and 2 μl of terminal transferase (NEB cat
#M0315S) to block the ﬁrst strand. The reaction was incubated at
37 °C for 1 h. EDTA was added to the ﬁnal concentration of 20 mM to
stop the reaction. To the resulting primer extension product, 5 μl
Streptavidin-coated magnetic beads was added (Invitrogen, Cat
#65001), and the sample incubated at room temperature for
20 min. The collected beads were washed ﬁrst with 100 μl NaOH
(0.1 M) by pipetting up and down, and incubated for 5 min at room
temperature. The beads were washed with water twice, then 1 μl of
sequencing Primer A-Random (100 μM) (5′-GCTGATGCTACGACCA-
CAGGNNNNNNN-3′, note that the speciﬁc sequence at the 5′ portion
corresponds to the primer for sequencing on the Illumina ﬂowcell)
was added to the beads along with 5 μl of 10X standard Taq DNA
polymerase buffer (NEB), 1 μl 10 mM dNTPs, and water up to 49 μl.
The reaction was initiated by adding 1 μl of Taq DNA polymerase (5 μl,
NEB) and incubated at 25 °C for 1 h, 72 °C for 30 s to extend, and then
75 °C for 5 min. EDTA was added up to a ﬁnal concentration of 10 mM
to stop the reaction. The beads werewashed twicewith 150 μl of wash
buffer (10 mM Tris, pH 7.5, 1 mM EDTA, 0.1% Tween-80 or Triton-X
100) and re-suspended in 20 μl water and heated for 5 min at 95 °C to
release the products extended from the random primer.
The released DNA was ampliﬁed for 18 cycles using a common
primer (Primer B: 5′-CAAGCAGAAGACGGCATACGAG-3′) in combina-
tion with a bar-coded PCR primer (5′-AATGATACGGCGACCACCGAGA-
TXXXX-GCTGATGCTACGACCACAGG-3′, note that the speciﬁc se-
quence at the 5′ portion corresponds to Primer A or P5 on the
Illlumon ﬂowcell and that the speciﬁc sequence after the bar-code
region corresponds to the sequencing primer).
The PCR products were precipitated with EtOH in the presence of
glycogen (1:100), and resuspended 10 μl water. The PCR products
were fractionated on a 10% acrylamide gel. DNA fragments in the 150–
350 nt rangewere cut out, elutedwith the elution buffer (10 mMTris-
pH 7.5, 1 mM EDTA, 0.1% Triton X-100), and subjected to sequencing
on the Illumina GAII Gene Analyzer.
4.3. Analysis of RNA-seq data
The analysis was done by using in-house made scripts, which used
bx-python (http://bx-python.trac.bx.psu.edu), kent source [30], and
BEDTools [31]. Fastq ﬁles were aligned with Bowtie [32] to merged
transcript sequences from the UCSC Known Gene Database [33,34].
The parameter for the mapping program Bowtie was “–solexa1.3-
quals -l25 -n2 -e 200 -m1 –best –strata –trim5 4” [32]. The mapping
started at the 5th position of each tag to increase higher rate and up to
2 mismatches were allowed. The unmapped tags in the ﬁrst round
were then mapped to the genome (hg18). The internal priming was
checked for each tag in its 300 nt downstream sequence to see
whether there was at least one polyA stretch (consecutive 8 As or 9 As
in a 10 nt window) [12]. Differential expression between TLS knock-
down and control was assessed using the edgeR package in R [35].
4.4. Microarray analysis and comparison with MAPS
Total RNA was isolated from control and TLS knockdown samples
in triplicate and applied to Illumina BeadChip (HumanHT-12 v4)
containing ~48 K probes. Array hybridization was performed at the
UCSD Core facility according to manufacturer's protocol. Quantile
271K. Fox-Walsh et al. / Genomics 98 (2011) 266–271normalization was performed in R using the lumi package [36].
Differential expression was measured in R using the limma package
[37]. A False Discovery Rate of 0.05 was applied to the resulting p-
values to correct for multiple-hypothesis testing.
Data from RNA-seq and microarrays were merged on the Gene
Symbol. For comparison of control gene expression, 1 was added to
the RNA-seq counts before taking the log in order to avoid log of 0. For
comparison of differentially expressed genes, we limited the analysis
to genes that had at least one tag in one replicate under each
condition.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.ygeno.2011.04.003.
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